GlassScriptPhysician profile
Mitchell H Paulin
NPI 1306930243
$229,295.82
in general payments reported to CMS, 2019-2025
12 companies · $8,310 in 2025
The $8,310 reported for 2025 was more than what 98% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $17K · 2021: $47K · 2022: $57K · 2023: $60K · 2024: $13K · 2025: $8,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $16K · Travel and Lodging: $9,502 · Food and Beverage: $3,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,415.00 |
| Consulting Fee | $15,991.17 |
| Travel and Lodging | $9,501.70 |
| Food and Beverage | $3,076.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $99,841.57 | 2019-2025 | Dysport |
| Allergan, INC. | $58,353.29 | 2019-2022 | |
| Abbvie INC. | $51,903.62 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $16,290.67 | 2022-2025 | Xeomin |
| Medtronic, INC. | $1,873.04 | 2021-2022 | |
| Ipsen Pharma Sas | $478.64 | 2019 | |
| Revance Therapeutics, INC. | $247.86 | 2024-2025 | Daxxify, Daxi |
| Piramal Critical Care | $101.76 | 2019 | |
| Merz North America, INC. | $87.93 | 2019 | |
| Medtronic USA, INC. | $71.18 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $34.74 | 2022-2023 | Ongentys, Ingrezza |
| Mdd US Operations, LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Paulin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.